Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris plus AVD in advanced classical Hodgkin lymphoma
NCT01712490Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2012
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by Takeda. Primary endpoint: Modified Progression-Free Survival at 4 years. Started Nov 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT01712490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712490.